Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124965823 | 12496582 | 3 | F | 20160505 | 20160823 | 20160624 | 20160825 | PER | PHEH2016US015733 | NOVARTIS | 82.17 | YR | M | Y | 143.00000 | KG | 20160825 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124965823 | 12496582 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG, UNK | N | 4345A | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | |||||
| 124965823 | 12496582 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 OT, PER DAY | N | 22083 | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124965823 | 12496582 | 1 | Dementia Alzheimer's type |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124965823 | 12496582 | Drug ineffective | |
| 124965823 | 12496582 | Product adhesion issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124965823 | 12496582 | 2 | 20150506 | 0 |